WASHINGTON, June 14 -- Alora Pharmaceuticals LLC, Alpharetta, Georgia, has submitted comments to the U.S. Department of Commerce Bureau of Industry and Security, regarding its Section 232 national security investigation on pharmaceutical imports. The company highlighted severe challenges posed by foreign competition to domestic production. Harold Arthur Deas Jr., CEO of Alora, explained the difficulty U.S. manufacturers face: "The market for Venlafaxine ER tablets is extremely competitive, with  more